Search company, investor...

Moleac

moleac.net

Founded Year

2003

Stage

Unattributed VC | Alive

About Moleac

Moleac is a specialty pharma company which identifies promising traditional Chinese medicines (TCMs) and which develops them as Western medicine ("modernizing" TCMs)

Headquarters Location

11 Biopolis Way Helios 09-07/08

Singapore

Missing: Moleac's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Moleac's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Moleac Patents

Moleac has filed 9 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Neurological disorders
  • Peripheral nervous system disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/13/2016

11/5/2019

Astragalus, Neurological disorders, Medicinal plants, Calcium channel blockers, NatureServe critically imperiled species

Grant

Application Date

9/13/2016

Grant Date

11/5/2019

Title

Related Topics

Astragalus, Neurological disorders, Medicinal plants, Calcium channel blockers, NatureServe critically imperiled species

Status

Grant

Latest Moleac News

Moleac launches CognivAiD™, a novel targeted product for vascular dementia

Jan 16, 2023

Author of the article: CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia. CognivAiD demonstrated significant and clinically meaningful disease-modifying benefits in clinical trials based on VaDAS-Cog and ADCS-CGIC scales, with a favourable safety profile. CognivAiD has a unique ‘multimodal mechanism of action’, reinforcing Moleac’s dedication to developing scientifically proven innovative formulations for patients with neurological conditions. We apologize, but this video has failed to load. Try refreshing your browser, or Advertisement 2 Article content SINGAPORE, Jan. 16, 2023 (GLOBE NEWSWIRE) — Moleac announced on 29th October 2022 the launch of CognivAiD™, the first-in-market specific product for Vascular Dementia (VaD). An optimized formulation of active extracts from Gingko, Ginseng and Saffron, CognivAiD shows significant and clinically meaningful disease-modifying benefits in patients with VaD, a condition with no targeted treatment at present. Financial Post Top Stories Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc. Email Address Sign Up By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails or any newsletter. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300 Thanks for signing up! A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Financial Post Top Stories will soon be in your inbox. We encountered an issue signing you up. Please try again Article content David Picard, CEO of Moleac, commented on the launch: “Moleac focuses on neurology to help patients reconnect with their lives. Over the past 20 years, we have built a unique platform to develop and bring to patients innovative medicines meeting their needs in neurology. This was done with our flagship product NeuroAiD™II, which currently benefits patients from over 35 countries. Our strategy now is to leverage our expertise, infrastructure and partners to bring more therapies to those suffering from a loss of brain functions. We are very proud to launch CognivAiD which fills a big gap in the treatment of vascular dementia and the cognitive disorders it causes.” Advertisement 3 Article content More than 55 million people currently live with dementia globally, with an incidence of over 10 million cases every year. This presents a huge financial and economic burden, amounting to an annual global cost of US$1.3 trillion that is expected to rise to US$2.8 trillion by 2030 1 . Vascular dementia, the second most common subtype of dementia after Alzheimer’s disease, accounts for 15-30% of all dementia cases 2 . The current treatment options for VaD include acetylcholinesterase inhibitors (AChE inhibitors) such as donepezil, and NMDA antagonists such as memantine. However, these options do not specifically target the key mechanisms of VaD. “There are currently very few therapeutic options available for patients with VaD. The existing options are non-specific with modest documented benefits, and they may have undesirable side effects in this frail population. Thanks to years of research in the lab and in clinical trials, CognivAiD is now available as a new therapeutic option, slowing down the cognitive decline of VaD patients and helping them to maintain their daily living activities. It targets the complex disease pathways of VaD via its properties of vascular protection, vasoregulation, and modulation of neuroinflammation. Its efficacy and safety are well-established in rigorous clinical trials published in peer-reviewed journals. We are proud at Moleac to provide access to CognivAiD, a new safe and effective treatment that will benefit VaD patients and their caregivers,” said Dr. Sylvain Durrleman, Head of Medical Affairs at Moleac. Advertisement 4 Article content About CognivAiD™ CognivAiD is an evidence-based formulation comprising active extracts from Croci Stigma, Ginkgo Folium and Ginseng Radix et Rhizoma which has been shown to be safe and effective for the treatment of vascular dementia. About Moleac Moleac is a biopharmaceutical company committed to helping patients and families reconnect with their lives. Headquartered in Singapore, we are dedicated to developing scientifically proven innovative formulations that bridge therapeutic gaps and address unmet needs of patients with neurological conditions such as stroke, traumatic brain injuries and dementia. Moleac’s flagship product NeuroAiD™II reaches more than 30,000 patients in over 35 countries every year. CognivAiD™, the company’s new product for vascular dementia, was launched in October 2022. For more information, visit www.moleac.com . Name of Press Contact: Clement Dif Phone: +65 6211 3710

Moleac Frequently Asked Questions (FAQ)

  • When was Moleac founded?

    Moleac was founded in 2003.

  • What is Moleac's latest funding round?

    Moleac's latest funding round is Unattributed VC.

  • Who are the investors of Moleac?

    Investors of Moleac include Hunza Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.